{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:07:01Z","timestamp":1759838821937},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>We implemented oral fluid (OF) as an alternative specimen type to urine for detection of cocaine (COC) and opiate abuse in outpatient addiction medicine clinics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We implemented a 2-\u03bcg\/L limit of quantification OF LC-MS\/MS assay and compiled and reviewed all findings from a 22-month collection period for COC, benzoylecgonine (BZE), codeine (COD), 6-acetylmorphine (MAM), and morphine (MOR). We also compared the results of our clinical samples at different OF cutoffs and analytes specified in the new 2015 SAMHSA OF guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Of 3608 OF samples, COC and BZE were positive in 593 and 508, respectively. COC or BZE was positive in 662 samples. Importantly and unexpectedly, 154 samples were COC positive and BZE negative, with 125 having COC 2.0\u20137.9 \u03bcg\/L. A simulation with the new guideline cutoffs confirmed 65% (430 of 662) of all COC- or BZE-positive data set samples. Similarly, the new guidelines confirmed 44% (263 of 603) of data set samples positive for MOR or COD. Simulation found that the new, lower MAM guideline cutoffs detected 89% of the 382 MAM-positive samples in the data set, 104 of which the new guidelines had identified as negative for MOR and COD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>COC (not BZE) is the dominant low-concentration OF analyte in an addiction medicine setting. This information will aid OF test interpretation. It also illustrates the importance of the 2015 guideline's new immunoassay cross-reactivity requirements and the likely improvement in detection of heroin use stemming from the new, lower MAM cutoffs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1373\/clinchem.2015.251066","type":"journal-article","created":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T23:29:00Z","timestamp":1458257340000},"page":"773-780","source":"Crossref","is-referenced-by-count":15,"title":["The New Substance Abuse and Mental Health Services Administration Oral Fluid Cutoffs for Cocaine and Heroin-Related Analytes Applied to an Addiction Medicine Setting: Important, Unanticipated Findings with LC-MS\/MS"],"prefix":"10.1093","volume":"62","author":[{"given":"James G","family":"Flood","sequence":"first","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahira","family":"Khaliq","sequence":"first","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth A","family":"Bishop","sequence":"first","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A","family":"Griggs","sequence":"first","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,5,1]]},"reference":[{"key":"2020022605333727000_B1","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1373\/clinchem.2008.108670","article-title":"Oral fluid testing for drugs of abuse","volume":"55","author":"Bosker","year":"2009","journal-title":"Clin Chem"},{"key":"2020022605333727000_B2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1258\/acb.2011.011116","article-title":"Screening for drugs of abuse: which matrix, oral fluid or urine?","volume":"48","author":"Allen","year":"2011","journal-title":"Ann Clin Biochem"},{"key":"2020022605333727000_B3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1196\/annals.1384.037","article-title":"Interpretation of oral fluid tests for drugs of abuse","volume":"1098","author":"Cone","year":"2007","journal-title":"Ann NY Acad Sci"},{"key":"2020022605333727000_B4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00007691-200404000-00020","article-title":"Detection times of drugs of abuse in blood, urine, and oral fluid","volume":"26","author":"Verstraete","year":"2004","journal-title":"Ther Drug Monit"},{"key":"2020022605333727000_B5","first-page":"19673","article-title":"Proposed revisions to mandatory guidelines for federal workplace drug testing programs","volume":"69","author":"Department of Health and Human Services","year":"2004","journal-title":"Federal Register"},{"key":"2020022605333727000_B6","first-page":"28054","article-title":"Proposed revisions to mandatory guidelines for federal workplace drug testing programs","volume":"80","author":"Department of Health and Human Services","year":"2015","journal-title":"Federal Register"},{"key":"2020022605333727000_B7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jat\/19.6.359","article-title":"Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma","volume":"19","author":"Jenkins","year":"1995","journal-title":"J Anal Toxicol"},{"key":"2020022605333727000_B8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/jat\/21.6.465","article-title":"Cocaine disposition in saliva following intravenous, intranasal, and smoked administration","volume":"21","author":"Cone","year":"1997","journal-title":"J Anal Toxicol"},{"key":"2020022605333727000_B9","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/FTD.0b013e3181f2b729","article-title":"Pharmacokinetics of cocaine and metabolites in human oral fluid and correlation with plasma concentrations after controlled administration","volume":"32","author":"Scheidweiler","year":"2010","journal-title":"Ther Drug Monit"},{"key":"2020022605333727000_B10","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/jat\/30.7.458","article-title":"Effect of repeated cocaine administration on detection times in oral fluid and urine","volume":"30","author":"Jufer","year":"2006","journal-title":"J Anal Toxicol"},{"key":"2020022605333727000_B11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/jat\/24.7.467","article-title":"Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers","volume":"24","author":"Jufer","year":"2000","journal-title":"J Anal Toxicol"},{"key":"2020022605333727000_B12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.forsciint.2012.03.021","article-title":"Presence of psychoactive substances in oral fluid from randomly selected drivers in Denmark","volume":"221","author":"Simonsen","year":"2012","journal-title":"Forensic Sci Int"},{"key":"2020022605333727000_B13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.drugalcdep.2006.08.020","article-title":"Oral fluid as an alternative matrix to monitor cocaine and opiate use in substance-abuse treatment patients","volume":"87","author":"Dams","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"2020022605333727000_B14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/jat\/30.6.370","article-title":"Acetylcodeine as a marker of illicit heroin abuse in oral fluid samples","volume":"30","author":"Phillips","year":"2006","journal-title":"J Anal Toxicol"},{"key":"2020022605333727000_B15","first-page":"130","article-title":"Oral fluid testing for drugs of abuse: positive prevalence rates by intercept immunoassay screening and GC-MS-MS confirmation and suggested cutoff concentrations","volume":"25","author":"Cone","year":"2002","journal-title":"J Anal Toxicol"},{"key":"2020022605333727000_B16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jat\/31.8.424","article-title":"Prevalence and disposition of drugs of abuse and opioid treatment drugs in oral fluid","volume":"31","author":"Cone","year":"2007","journal-title":"J Anal Toxicol"},{"key":"2020022605333727000_B17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/anatox\/35.1.32","article-title":"Oral fluid is a viable alternative for monitoring drug abuse: detection of drugs in oral fluid by liquid chromatography-tandem mass spectrometry and comparison to the results from urine samples from patients treated with methadone or buprenorphine","volume":"35","author":"Vindenes","year":"2011","journal-title":"J Anal Toxicol"},{"key":"2020022605333727000_B18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/jat\/33.9.569","article-title":"Identification and quantitation of amphetamines, cocaine, opiates, and phencyclidine in oral fluid by liquid chromatography-tandem mass spectrometry","volume":"33","author":"Fritch","year":"2009","journal-title":"J Anal Toxicol"},{"key":"2020022605333727000_B19","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1373\/clinchem.2006.074237","article-title":"Drug screening of preserved oral fluid by liquid chromatography\u2013tandem mass spectrometry","volume":"53","author":"\u00d8iestad","year":"2007","journal-title":"Clin Chem"},{"key":"2020022605333727000_B20","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal Chem"},{"key":"2020022605333727000_B21","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1016\/j.jchromb.2011.09.002","article-title":"Drugs of abuse in oral fluid collected by two different sample kits\u2014stability testing and validation using ultra performance tandem mass spectrometry analysis","volume":"879","author":"Lund","year":"2011","journal-title":"J Chromatogr B"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/62\/5\/773\/32644307\/clinchem0773.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/62\/5\/773\/32644307\/clinchem0773.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T05:34:51Z","timestamp":1582695291000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/62\/5\/773\/5611782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,1]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,1]]},"published-print":{"date-parts":[[2016,5,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2015.251066","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,5,1]]},"published":{"date-parts":[[2016,5,1]]}}}